Key result
This review outlines the current status of animal and human vaccine models targeting Norovirus and addresses the factors hampering the development of a broadly effective vaccine.
This review highlights the current progress and challenges in developing a broadly effective vaccine against Norovirus.
Identifies barriers blocking Norovirus vaccine progress; leaves open targeted research to achieve broad efficacy.
Norovirus (NoV) is responsible for at least 50% of all gastroenteritis outbreaks worldwide. NoVs are classified into 6 different genogroups (GGI- GGVI) based on the viral capsid protein with NoV genogroup II genotype 4 (GII.4) being the predominant strain causing human diseases. Supportive therapy involving reversal of dehydration and electrolyte deficiency is the main treatment of NoV gastroenteritis. However, the worldwide increased recognition of NoV as an important agent of diarrheal gastroenteritis prompted researchers to focus on establishing preventive strategies conferring long-lasting immunity. This review describes the current status of animal and human vaccine models/studies targeting NoV and addresses the factors hampering the development of a broadly effective vaccine.
No takes yet. Share an insight, caveat, or question.
Nada M. Melhem (2016) conducted a review in Norovirus gastroenteritis. Norovirus vaccines was evaluated. This review outlines the current status of animal and human vaccine models targeting Norovirus and addresses the factors hampering the development of a broadly effective vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: